BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21395650)

  • 1. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
    Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
    Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
    Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
    BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
    Dorababu P; Nagesh N; Linga VG; Gundeti S; Kutala VK; Reddanna P; Digumarti R
    Eur J Clin Pharmacol; 2012 Apr; 68(4):379-87. PubMed ID: 22009189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
    Stocco G; Cheok MH; Crews KR; Dervieux T; French D; Pei D; Yang W; Cheng C; Pui CH; Relling MV; Evans WE
    Clin Pharmacol Ther; 2009 Feb; 85(2):164-72. PubMed ID: 18685564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
    Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
    Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
    Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
    Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
    Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
    J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.
    Tanaka Y; Manabe A; Nakadate H; Kondoh K; Nakamura K; Koh K; Utano T; Kikuchi A; Komiyama T
    Leuk Res; 2012 May; 36(5):560-4. PubMed ID: 22200619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.
    Farfan MJ; Salas C; Canales C; Silva F; Villarroel M; Kopp K; Torres JP; Santolaya ME; Morales J
    BMC Cancer; 2014 Apr; 14():299. PubMed ID: 24774509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.
    Zhou Y; Wang L; Zhai XY; Wen L; Tang F; Yang F; Liu XT; Dong L; Zhi LJ; Shi HY; Hao GX; Zheng Y; Jacqz-Aigrain E; Wang TY; Zhao W
    Br J Clin Pharmacol; 2020 Aug; 86(8):1519-1527. PubMed ID: 32077136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
    Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
    Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.